France's Transgene has said that it is focusing its R&D efforts on whatit believes to be its most promising product candidate in the area of cancer immunotherpy. Along with this, the firm has as its priority the establishment of partnerships on its product candidates and technology platforms.
Transgene currently has two cancer vaccine product candidates in clinical trials. One uses the Muc1 antigen for the treatment of breast, prostate, lung and a variety of other cancers. The company says it has completed Phase I and II clinical trials in patients with breast and prostate cancers using an earlier-generation vaccinia vector, the trials of which demonstrated the potential for the safety and efficacy of this family of vectors.
In addition, a new formulation of a Muc1 vaccine product candidate, which uses a new-generation vector based on the Modified Virus Ankara strain, has shown improved efficacy and demonstrated safety in preclinical studies as well as in Phase I clinical trials. Based on these results, Transgene decided to discontinue development of the product candidate using the earlier-generation vaccinia virus vector. Phase II clinical trials of the MVA-Muc1-IL2 product candidate are scheduled to begin in the fourth quarter of 2001, in Europe and the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze